Sotatercept boosts exercise tolerance in PAH by raising hemoglobin (partly via decongestion), improving RV‑PA coupling and CO reserve, & increasing skeletal muscle O₂ delivery & utilization, all while reducing RV workload.
Get the details in #JACC: https://bit.ly/40JGHj7 #THT2026 #cvPAH #CardioSky
According to the phase 3 HYPERION trial conducted by Vallerie V. McLaughlin, MD, FACC, et al., adding sotatercept to standard care lowers the risk of clinical worsening in patients recently diagnosed with #cvPAH.
📰 Read the full article: https://bit.ly/4q2pE7w
#CardioSky
ZENITH: Sotatercept, a first-in-class novel activin-signaling inhibitor, led to a 76% lower risk of a composite of death from any cause, lung transplantation or 🏥 for worsening #cvPAH compared to placebo in high-risk adults with PAH.
Learn more: bit.ly/3G16Rqv #ACC25
#CardioSky #MedSky
